{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:11:39Z","timestamp":1793765499550,"version":"4.6.1"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Health\/National Cancer Institute","award":["K08CA245100"],"award-info":[{"award-number":["K08CA245100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-06030-y","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:06:58Z","timestamp":1776100018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathogenesis and kidney prognosis of renal amyloidosis"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-2316","authenticated-orcid":false,"given":"Alvin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-6299","authenticated-orcid":false,"given":"Raad B.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"1","key":"6030_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-136456","volume":"136","author":"RS Szor","year":"2020","unstructured":"Szor RS, Fernandes F, Seguro FS et al (2020) Challenges in diagnosis and treatment of systemic amyloidosis: 10 years of experience in a public Brazilian University Center. Blood 136(1):6\u20138. https:\/\/doi.org\/10.1182\/blood-2020-136456","journal-title":"Blood"},{"issue":"11","key":"6030_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2217\/cer-2018-0062","volume":"7","author":"TP Quock","year":"2018","unstructured":"Quock TP, Chang E, Munday JS, D\u2019Souza A, Gokhale S, Yan T (2018) Mortality and healthcare costs in medicare beneficiaries with AL amyloidosis. J Comp Eff Res 7(11):1053\u20131062. https:\/\/doi.org\/10.2217\/cer-2018-0062","journal-title":"J Comp Eff Res"},{"issue":"84","key":"6030_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/j.ajkd.2024.01.530","volume":"2024","author":"N Leung","year":"2024","unstructured":"Leung N, Nasr SH (2024) Update on classification, etiology, and typing of renal amyloidosis: a review. Am J Kidney Dis 2024(84):361\u2013373. https:\/\/doi.org\/10.1053\/j.ajkd.2024.01.530","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"6030_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11926-024-01147-8","volume":"26","author":"S Mirioglu","year":"2024","unstructured":"Mirioglu S, Uludag O, Hurdogan O et al (2024) AA amyloidosis: a contemporary view. Curr Rheumatol Rep 26(7):248\u2013259. https:\/\/doi.org\/10.1007\/s11926-024-01147-8","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"6030_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40620-017-0426-6","volume":"31","author":"S Sethi","year":"2018","unstructured":"Sethi S, Theis JD (2018) Pathology and diagnosis of renal non-AL amyloidosis. J Nephrol 31(3):343\u2013350. https:\/\/doi.org\/10.1007\/s40620-017-0426-6","journal-title":"J Nephrol"},{"issue":"1","key":"6030_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-47","volume":"4","author":"M Rosenzweig","year":"2011","unstructured":"Rosenzweig M, Landau H (2011) Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol 4(1):47. https:\/\/doi.org\/10.1186\/1756-8722-4-47","journal-title":"J Hematol Oncol"},{"key":"6030_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.915420","volume":"12","author":"C Berkowitz","year":"2022","unstructured":"Berkowitz C, Dittus C (2022) Diagnosis and management of AL amyloidosis due to B-cell non-Hodgkin lymphoma. Front Oncol 12:915420. https:\/\/doi.org\/10.3389\/fonc.2022.915420","journal-title":"Front Oncol"},{"issue":"9","key":"6030_CR8","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2215\/CJN.10491012","volume":"8","author":"SM Said","year":"2013","unstructured":"Said SM, Sethi S, Valeri AM et al (2013) Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 8(9):1515. https:\/\/doi.org\/10.2215\/CJN.10491012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"6030_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1097\/PAS.0b013e3181abdfa7","volume":"33","author":"H von Hutten","year":"2009","unstructured":"von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, R\u00f6cken C (2009) Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol 33(8):1198. https:\/\/doi.org\/10.1097\/PAS.0b013e3181abdfa7","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"6030_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS (2018) Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2(10):1046\u20131053. https:\/\/doi.org\/10.1182\/bloodadvances.2018016402","journal-title":"Blood Adv"},{"issue":"1","key":"6030_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02414-6","volume":"17","author":"N Kumar","year":"2022","unstructured":"Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV (2022) Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis 17(1):278. https:\/\/doi.org\/10.1186\/s13023-022-02414-6","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"6030_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"R Kyle","year":"1992","unstructured":"Kyle R, Linos A, Beard C et al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]. Blood 79(7):1817\u20131822. https:\/\/doi.org\/10.1182\/blood.V79.7.1817.1817","journal-title":"Blood"},{"issue":"21","key":"6030_CR13","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2014-12-618108","volume":"125","author":"MD Benson","year":"2015","unstructured":"Benson MD, Liepnieks JJ, Kluve-Beckerman B (2015) Hereditary systemic immunoglobulin light-chain amyloidosis. Blood 125(21):3281\u20133286. https:\/\/doi.org\/10.1182\/blood-2014-12-618108","journal-title":"Blood"},{"key":"6030_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110635","author":"A Solomon","year":"1982","unstructured":"Solomon A, Frangione B, Franklin EC (1982) Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest. https:\/\/doi.org\/10.1172\/JCI110635","journal-title":"J Clin Invest"},{"issue":"12","key":"6030_CR15","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1073\/pnas.91.12.5446","volume":"91","author":"MR Hurle","year":"1994","unstructured":"Hurle MR, Helms LR, Li L, Chan W, Wetzel R (1994) A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci 91(12):5446\u20135450. https:\/\/doi.org\/10.1073\/pnas.91.12.5446","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"6030_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/13506120009146835","volume":"7","author":"FJ Stevens","year":"2000","unstructured":"Stevens FJ (2000) Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7(3):200\u2013211. https:\/\/doi.org\/10.3109\/13506120009146835","journal-title":"Amyloid"},{"issue":"4","key":"6030_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jmr.681","volume":"17","author":"JS Wall","year":"2004","unstructured":"Wall JS, Gupta V, Wilkerson M et al (2004) Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four V\u03bb6 proteins. J Mol Recognit 17(4):323\u2013331. https:\/\/doi.org\/10.1002\/jmr.681","journal-title":"J Mol Recognit"},{"issue":"Supplement 1","key":"6030_CR18","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1182\/blood.V130.Suppl_1.4339.4339","volume":"130","author":"EB Martin","year":"2017","unstructured":"Martin EB, Williams A, Heidel RE, Lands RH, Kennel SJ, Wall JS (2017) A method to identify patients with multiple myeloma who are at risk of developing concomitant amyloidosis. Blood 130(Supplement 1):4339. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.4339.4339","journal-title":"Blood"},{"issue":"3","key":"6030_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","volume":"100","author":"V Perfetti","year":"2002","unstructured":"Perfetti V, Casarini S, Palladini G et al (2002) Analysis of V\u03bb-J\u03bb expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(\u03bbIII) as a new amyloid-associated germline gene segment. Blood 100(3):948\u2013953. https:\/\/doi.org\/10.1182\/blood-2002-01-0114","journal-title":"Blood"},{"issue":"5","key":"6030_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ekir.2021.02.014","volume":"6","author":"GA Herrera","year":"2021","unstructured":"Herrera GA, del Pozo-Yauner L, Teng J et al (2021) Glomerulopathic light Chain-Mesangial cell interactions: Sortilin-Related receptor (SORL1) and signaling. Kidney Int Rep 6(5):1379\u20131396. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.014","journal-title":"Kidney Int Rep"},{"issue":"5","key":"6030_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/labinvest.3780278","volume":"81","author":"WJ Russell","year":"2001","unstructured":"Russell WJ, Cardelli J, Harris E, Baier RJ, Herrera GA (2001) Monoclonal light chain\u2013mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest 81(5):689\u2013703. https:\/\/doi.org\/10.1038\/labinvest.3780278","journal-title":"Lab Invest"},{"issue":"4","key":"6030_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/labinvest.3700069","volume":"84","author":"J Teng","year":"2004","unstructured":"Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA (2004) Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Investig J Tech Methods Pathol 84(4):440\u2013451. https:\/\/doi.org\/10.1038\/labinvest.3700069","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"11","key":"6030_CR23","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.ekir.2020.07.013","volume":"5","author":"GA Herrera","year":"2020","unstructured":"Herrera GA, Teng J, Turbat-Herrera EA, Zeng C, Del Pozo-Yauner L (2020) Understanding mesangial pathobiology in AL-Amyloidosis and monoclonal Ig light chain deposition disease. Kidney Int Rep 5(11):1870\u20131893 PMID: 33163710; PMCID: PMC7609979","journal-title":"Kidney Int Rep"},{"issue":"2","key":"6030_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/01913123.2025.2468708","volume":"49","author":"GA Herrera","year":"2025","unstructured":"Herrera GA, Teng J, Zeng C, Del Pozo-Yauner L, Liu B, Turbat-Herrera EA (2025) Identifying gene expression and cellular pathways involved in glomerular AL-amyloidosis and correlation with experimental data: seeking novel therapeutic interventions. Ultrastruct Pathol 49(2):216\u2013234. https:\/\/doi.org\/10.1080\/01913123.2025.2468708","journal-title":"Ultrastruct Pathol"},{"issue":"4","key":"6030_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/hemato4040028","volume":"4","author":"GA Herrera","year":"2023","unstructured":"Herrera GA, Teng J, Zeng C, Del Pozo-Yauner L, Liu B, Turbat-Herrera EA (2023) Fibril-Forming organelles in mesangial cells in renal biopsies from patients with Light-Chain-Associated amyloidosis. Hemato 4(4):350\u2013363. https:\/\/doi.org\/10.3390\/hemato4040028","journal-title":"Hemato"},{"issue":"2","key":"6030_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3109\/01913123.2013.861568","volume":"38","author":"J Teng","year":"2014","unstructured":"Teng J, Turbat-Herrera EA, Herrera GA (2014) Extrusion of amyloid fibrils to the extracellular space in experimental mesangial AL-amyloidosis: transmission and scanning electron microscopy studies and correlation with renal biopsy observations. Ultrastruct Pathol 38(2):104\u2013115. https:\/\/doi.org\/10.3109\/01913123.2013.861568","journal-title":"Ultrastruct Pathol"},{"issue":"1","key":"6030_CR27","first-page":"290","volume":"74","author":"YM Tagouri","year":"1996","unstructured":"Tagouri YM, Sanders PW, Picken MM, Siegal GP, Kerby JD, Herrera GA (1996) In vitro AL-amyloid formation by rat and human mesangial cells. Lab Investig J Tech Methods Pathol 74(1):290\u2013302","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"4","key":"6030_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3109\/13506129809007296","volume":"5","author":"J Isaac","year":"1998","unstructured":"Isaac J, Kerby JD, Russell WJ, Dempsey SC, Sanders PW, Herrera GA (1998) In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid 5(4):238\u201346. https:\/\/doi.org\/10.3109\/13506129809007296","journal-title":"Amyloid"},{"key":"6030_CR29","doi-asserted-by":"publisher","DOI":"10.1021\/bi00034a001","author":"FJ Stevens","year":"1995","unstructured":"Stevens FJ, Myatt EA, Chang CH et al (1995) A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry. https:\/\/doi.org\/10.1021\/bi00034a001","journal-title":"Biochemistry"},{"issue":"5","key":"6030_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1107\/s0907444902004183","volume":"58","author":"PC Bourne","year":"2002","unstructured":"Bourne PC, Ramsland PA, Shan L et al (2002) Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic properties. Acta Crystallogr D Biol Crystallogr 58(5):815\u2013823. https:\/\/doi.org\/10.1107\/s0907444902004183","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"10","key":"6030_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000981","volume":"2","author":"S Enqvist","year":"2007","unstructured":"Enqvist S, Sletten K, Stevens FJ, Hellman U, Westermark P (2007) Germ line origin and somatic mutations determine the target tissues in systemic AL-Amyloidosis. PLoS One 2(10):e981. https:\/\/doi.org\/10.1371\/journal.pone.0000981","journal-title":"PLoS One"},{"issue":"4","key":"6030_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/path.2607","volume":"219","author":"S Enqvist","year":"2009","unstructured":"Enqvist S, Sletten K, Westermark P (2009) Fibril protein fragmentation pattern in systemic AL-amyloidosis. J Pathol 219(4):473\u2013480. https:\/\/doi.org\/10.1002\/path.2607","journal-title":"J Pathol"},{"issue":"2","key":"6030_CR33","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1074\/jbc.M007766200","volume":"276","author":"YS Kim","year":"2001","unstructured":"Kim YS, Cape SP, Chi E et al (2001) Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains*. J Biol Chem 276(2):1626\u20131633. https:\/\/doi.org\/10.1074\/jbc.M007766200","journal-title":"J Biol Chem"},{"issue":"3","key":"6030_CR34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.kint.2023.11.023","volume":"105","author":"C Charalampous","year":"2024","unstructured":"Charalampous C, Dasari S, McPhail E et al (2024) A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis. Kidney Int 105(3):484\u2013495. https:\/\/doi.org\/10.1016\/j.kint.2023.11.023","journal-title":"Kidney Int"},{"issue":"11","key":"6030_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.75","volume":"1","author":"LA Sikkink","year":"2010","unstructured":"Sikkink LA, Ramirez-Alvarado M (2010) Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis 1(11):e98. https:\/\/doi.org\/10.1038\/cddis.2010.75","journal-title":"Cell Death Dis"},{"issue":"9","key":"6030_CR36","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1111\/jcmm.13691","volume":"22","author":"M Rizou","year":"2018","unstructured":"Rizou M, Frangou EA, Marineli F et al (2018) The family of 14-3-3 proteins and specifically 14-3-3\u03c3 are up-regulated during the development of renal pathologies. J Cell Mol Med 22(9):4139\u20134149. https:\/\/doi.org\/10.1111\/jcmm.13691","journal-title":"J Cell Mol Med"},{"key":"6030_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0348-x","volume":"17","author":"J Guo","year":"2016","unstructured":"Guo J, Guan Q, Liu X et al (2016) Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injury. BMC Nephrol 17:133. https:\/\/doi.org\/10.1186\/s12882-016-0348-x","journal-title":"BMC Nephrol"},{"issue":"6","key":"6030_CR38","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1053\/j.ajkd.2015.10.006","volume":"66","author":"AB Fogo","year":"2015","unstructured":"Fogo AB, Lusco MA, Najafian B, Alpers CE (2015) AJKD atlas of renal pathology: AL amyloidosis. Am J Kidney Dis 66(6):e43\u2013e45. https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.006","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"6030_CR39","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.2169\/internalmedicine.54.5174","volume":"54","author":"H Kato","year":"2015","unstructured":"Kato H, Fujigaki Y, Asakawa S et al (2015) Rapid deterioration of the renal function caused by the coexistence of intratubular amyloidosis and myeloma cast nephropathy. Intern Med 54(23):3023\u20133028. https:\/\/doi.org\/10.2169\/internalmedicine.54.5174","journal-title":"Intern Med"},{"issue":"3","key":"6030_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1440-1827.2001.01188.x","volume":"51","author":"M Nagata","year":"2001","unstructured":"Nagata M, Shimokama T, Harada A, Koyama A, Watanabe T (2001) Glomerular crescents in renal amyloidosis: an epiphenomenon or distinct pathology? Pathol Int 51(3):179\u2013186. https:\/\/doi.org\/10.1046\/j.1440-1827.2001.01188.x","journal-title":"Pathol Int"},{"issue":"4","key":"6030_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000168336","volume":"11","author":"C Orfila","year":"1991","unstructured":"Orfila C, Lepert JC, Modesto A, Bernadet P, Suc JM (1991) Fanconi\u2019s syndrome, kappa light-chain myeloma, non-amyloid fibrils and cytoplasmic crystals in renal tubular epithelium. Am J Nephrol 11(4):345\u2013349. https:\/\/doi.org\/10.1159\/000168336","journal-title":"Am J Nephrol"},{"issue":"6","key":"6030_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061744","volume":"13","author":"A Shafqat","year":"2024","unstructured":"Shafqat A, Elmaleh H, Mushtaq A et al (2024) Renal AL amyloidosis: updates on diagnosis, staging, and management. J Clin Med 13(6):1744. https:\/\/doi.org\/10.3390\/jcm13061744","journal-title":"J Clin Med"},{"issue":"6","key":"6030_CR43","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","volume":"29","author":"JH Pinney","year":"2011","unstructured":"Pinney JH, Lachmann HJ, Bansi L et al (2011) Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol 29(6):674\u2013681. https:\/\/doi.org\/10.1200\/JCO.2010.30.5235","journal-title":"J Clin Oncol"},{"issue":"3","key":"6030_CR44","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/ndt\/gfm684","volume":"23","author":"F Bergesio","year":"2008","unstructured":"Bergesio F, Ciciani AM, Manganaro M et al (2008) Renal involvement in systemic amyloidosis *: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transpl 23(3):941\u2013951. https:\/\/doi.org\/10.1093\/ndt\/gfm684","journal-title":"Nephrol Dial Transpl"},{"issue":"10","key":"6030_CR45","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","volume":"24","author":"MA Gertz","year":"2009","unstructured":"Gertz MA, Leung N, Lacy MQ et al (2009) Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 24(10):3132\u20133137. https:\/\/doi.org\/10.1093\/ndt\/gfp201","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"6030_CR46","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P et al (2014) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124(15):2325\u20132332. https:\/\/doi.org\/10.1182\/blood-2014-04-570010","journal-title":"Blood"},{"issue":"7","key":"6030_CR47","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ajh.24738","volume":"92","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, Gavriatopoulou M, Roussou M et al (2017) Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy. Am J Hematol 92(7):632\u2013639. https:\/\/doi.org\/10.1002\/ajh.24738","journal-title":"Am J Hematol"},{"issue":"2","key":"6030_CR48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2215\/CJN.02470607","volume":"3","author":"B Guery","year":"2008","unstructured":"Bolle[Combining Acute Accent]e G, Guery B, Joly D et al (2008) Presentation and outcome of patients with systemic amyloidosis undergoing Dialysis. Clin J Am Soc Nephrol 3(2):375. https:\/\/doi.org\/10.2215\/CJN.02470607","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"6030_CR49","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1093\/ndt\/gfp379","volume":"24","author":"P Ronco","year":"2009","unstructured":"Ronco P, Aucouturier P (2009) Renal involvement in AL amyloidosis: the facts, the promise and the hope *. Nephrol Dial Transplant 24(10):2967\u20132969. https:\/\/doi.org\/10.1093\/ndt\/gfp379","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"6030_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00428-0","volume":"11","author":"G Palladini","year":"2021","unstructured":"Palladini G, Paiva B, Wechalekar A, Massa M, Milani P, Lasa M, Ravichandran S, Krsnik I, Basset M, Burgos L, Nuvolone M, Lecumberri R, Foli A, Puig N, Sesta MA, Bozzola M, Cascino P, Nevone A, Ripepi J, Berti P, Casarini S, Annibali O, Orfao A, San-Miguel J, Merlini G (2021) Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J 11(2):34. https:\/\/doi.org\/10.1038\/s41408-021-00428-0","journal-title":"Blood Cancer J"},{"issue":"1","key":"6030_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-54","volume":"7","author":"E Desport","year":"2012","unstructured":"Desport E, Bridoux F, Sirac C et al (2012) AL amyloidosis. Orphanet J Rare Dis 7(1):54. https:\/\/doi.org\/10.1186\/1750-1172-7-54","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"6030_CR52","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV et al (2023) <article-title update=\"added\">2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0with cardiac amyloidosis. J Am Coll Cardiol 81(11):1076\u20131126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6030_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00085.x","volume":"61","author":"MA Gertz","year":"2002","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A (2002) Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 61(1):1\u20139. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00085.x","journal-title":"Kidney Int"},{"issue":"8","key":"6030_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00714-5","volume":"12","author":"A Havasi","year":"2022","unstructured":"Havasi A, Heybeli C, Leung N et al (2022) Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the International Kidney and Monoclonal Gammopathy Research Group. Blood Cancer J 12(8):1\u20138. https:\/\/doi.org\/10.1038\/s41408-022-00714-5","journal-title":"Blood Cancer J"},{"key":"6030_CR55","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","volume":"9","author":"KU Eckardt","year":"2009","unstructured":"Eckardt KU, Kasiske BL, Zeier MG (2009) Special issue: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9:S1\u2013S155. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x","journal-title":"Am J Transplant"},{"issue":"5","key":"6030_CR56","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1053\/j.ajkd.2006.02.174","volume":"47","author":"T Gono","year":"2006","unstructured":"Gono T, Yazaki M, Fushimi T et al (2006) AH amyloidosis associated with lymphoplasmacytic lymphoma secreting a monoclonal \u03b3 heavy chain carrying an unusual truncated D segment. Am J Kidney Dis 47(5):908\u2013914. https:\/\/doi.org\/10.1053\/j.ajkd.2006.02.174","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"6030_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ki.2012.414","volume":"83","author":"SH Nasr","year":"2013","unstructured":"Nasr SH, Said SM, Valeri AM et al (2013) The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 83(3):463\u2013470. https:\/\/doi.org\/10.1038\/ki.2012.414","journal-title":"Kidney Int"},{"issue":"1","key":"6030_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","volume":"7","author":"S Urieli-Shoval","year":"2000","unstructured":"Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7(1):64","journal-title":"Curr Opin Hematol"},{"key":"6030_CR59","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i4.40","author":"KK Eklund","year":"2012","unstructured":"Eklund KK, Niemi K, Kovanen PT (2012) Immune functions of serum amyloid A. Crit Rev Immunol. https:\/\/doi.org\/10.1615\/CritRevImmunol.v32.i4.40","journal-title":"Crit Rev Immunol"},{"issue":"2","key":"6030_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/13506120902879905","volume":"16","author":"CL Murphy","year":"2009","unstructured":"Murphy CL, Wang S, Kestler DP, Stevens FA, Weiss DT, Solomon A (2009) AA amyloidosis associated with a mutated serum amyloid A4 protein. Amyloid 16(2):84\u201388. https:\/\/doi.org\/10.1080\/13506120902879905","journal-title":"Amyloid"},{"issue":"1","key":"6030_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2019.1693359","volume":"27","author":"AF Brunger","year":"2020","unstructured":"Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC (2020) Causes of AA amyloidosis: a systematic review. Amyloid 27(1):1\u201312. https:\/\/doi.org\/10.1080\/13506129.2019.1693359","journal-title":"Amyloid"},{"issue":"2","key":"6030_CR62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/rheumatology\/kead465","volume":"63","author":"M Bektas","year":"2024","unstructured":"Bektas M, Koca N, Oguz E et al (2024) Characteristics and course of patients with AA amyloidosis: single centre experience with 174 patients from Turkey. Rheumatology 63(2):319\u2013328. https:\/\/doi.org\/10.1093\/rheumatology\/kead465","journal-title":"Rheumatology"},{"key":"6030_CR63","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S39981","volume":"6","author":"DRde As\u00faa","year":"2014","unstructured":"As\u00faa DRde, Costa R, Galv\u00e1n JM, Filigheddu MT, Trujillo D, Cadi\u00f1anos J (2014) Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 6:369. https:\/\/doi.org\/10.2147\/CLEP.S39981","journal-title":"Clin Epidemiol"},{"key":"6030_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejim.2023.05.015","volume":"115","author":"A Di Ciaula","year":"2023","unstructured":"Di Ciaula A, Iacoviello M, Bonfrate L et al (2023) Genetic and clinical features of familial mediterranean fever (FMF) in a homogeneous cohort of patients from South-Eastern Italy. Eur J Intern Med 115:79\u201387. https:\/\/doi.org\/10.1016\/j.ejim.2023.05.015","journal-title":"Eur J Intern Med"},{"issue":"2","key":"6030_CR65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.kint.2021.09.007","volume":"101","author":"J Sikora","year":"2022","unstructured":"Sikora J, Kmochov\u00e1 T, Mu\u0161\u00e1lkov\u00e1 D et al (2022) A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney Int 101(2):349\u2013359. https:\/\/doi.org\/10.1016\/j.kint.2021.09.007","journal-title":"Kidney Int"},{"key":"6030_CR66","unstructured":"SAA1 serum amyloid A1 [Homo sapiens (human)] - Gene - NCBI. Accessed October 21 (2024) https:\/\/www.ncbi.nlm.nih.gov\/gene\/6288"},{"issue":"23","key":"6030_CR67","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJB, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361\u20132371. https:\/\/doi.org\/10.1056\/NEJMoa070265","journal-title":"N Engl J Med"},{"issue":"16","key":"6030_CR68","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.febslet.2009.04.026","volume":"583","author":"GT Westermark","year":"2009","unstructured":"Westermark GT, Westermark P (2009) Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 583(16):2685\u20132690. https:\/\/doi.org\/10.1016\/j.febslet.2009.04.026","journal-title":"FEBS Lett"},{"key":"6030_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cytogfr.2015.12.010","volume":"30","author":"M De Buck","year":"2016","unstructured":"De Buck M, Gouwy M, Wang JM et al (2016) The cytokine-serum amyloid A-chemokine network. Cytokine Growth Factor Rev 30:55\u201369. https:\/\/doi.org\/10.1016\/j.cytogfr.2015.12.010","journal-title":"Cytokine Growth Factor Rev"},{"key":"6030_CR70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","volume":"10","author":"GT Westermark","year":"2015","unstructured":"Westermark GT, F\u00e4ndrich M, Westermark P (2015) AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol-Mech Dis 10:321\u2013344. https:\/\/doi.org\/10.1146\/annurev-pathol-020712-163913","journal-title":"Annu Rev Pathol-Mech Dis"},{"issue":"40","key":"6030_CR71","doi-asserted-by":"publisher","first-page":"16115","DOI":"10.1073\/pnas.1306621110","volume":"110","author":"JP Simons","year":"2013","unstructured":"Simons JP, Al-Shawi R, Ellmerich S et al (2013) Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A 110(40):16115\u201316120. https:\/\/doi.org\/10.1073\/pnas.1306621110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9275","key":"6030_CR72","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358(9275):24\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(00)05252-1","journal-title":"Lancet"},{"issue":"2","key":"6030_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00428-001-0582-9","volume":"440","author":"C R\u00f6cken","year":"2002","unstructured":"R\u00f6cken C, Shakespeare A (2002) Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440(2):111\u2013122. https:\/\/doi.org\/10.1007\/s00428-001-0582-9","journal-title":"Virchows Arch"},{"issue":"3","key":"6030_CR74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/13506120600877201","volume":"13","author":"SM Kinkley","year":"2006","unstructured":"Kinkley SM, Bagshaw WLG, Tam SP, Kisilevsky R (2006) The path of murine serum amyloid A through peritoneal macrophages. Amyloid 13(3):123\u2013134. https:\/\/doi.org\/10.1080\/13506120600877201","journal-title":"Amyloid"},{"issue":"3","key":"6030_CR75","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.kint.2022.10.028","volume":"103","author":"S Karam","year":"2023","unstructured":"Karam S, Haidous M, Royal V, Leung N (2023) Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int 103(3):473\u2013484. https:\/\/doi.org\/10.1016\/j.kint.2022.10.028","journal-title":"Kidney Int"},{"issue":"5","key":"6030_CR76","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1365-3083.1989.tb02468.x","volume":"30","author":"GT Westermark","year":"1989","unstructured":"Westermark GT, Sletten K, Westermark P (1989) Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 30(5):605\u2013613. https:\/\/doi.org\/10.1111\/j.1365-3083.1989.tb02468.x","journal-title":"Scand J Immunol"},{"issue":"23","key":"6030_CR77","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa065644","volume":"356","author":"LM Dember","year":"2007","unstructured":"Dember LM, Hawkins PN, Hazenberg BPC et al (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356(23):2349\u20132360. https:\/\/doi.org\/10.1056\/NEJMoa065644","journal-title":"N Engl J Med"},{"issue":"4","key":"6030_CR78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/ard.62.4.368","volume":"62","author":"P Verschueren","year":"2003","unstructured":"Verschueren P, Lensen F, Lerut E et al (2003) Benefit of anti-TNF\u03b1 treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 62(4):368\u2013369. https:\/\/doi.org\/10.1136\/ard.62.4.368","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6030_CR79","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.humpath.2007.04.013","volume":"38","author":"J Verine","year":"2007","unstructured":"Verine J, Mourad N, Desseaux K et al (2007) Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 38(12):1798\u20131809. https:\/\/doi.org\/10.1016\/j.humpath.2007.04.013","journal-title":"Hum Pathol"},{"issue":"8","key":"6030_CR80","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/ard.2010.143438","volume":"70","author":"L Obici","year":"2011","unstructured":"Obici L, Meini A, Cattalini M et al (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70(8):1511\u20131512. https:\/\/doi.org\/10.1136\/ard.2010.143438","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6030_CR81","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/14397595.2013.844294","volume":"24","author":"I Miyagawa","year":"2014","unstructured":"Miyagawa I, Nakayamada S, Saito K et al (2014) Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol 24(3):405\u2013409. https:\/\/doi.org\/10.3109\/14397595.2013.844294","journal-title":"Mod Rheumatol"},{"issue":"3","key":"6030_CR82","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13506129.2017.1352503","volume":"24","author":"T Lane","year":"2017","unstructured":"Lane T, Wechalekar,Ashutosh D, Gillmore, Julian D, Hawkins, Philip N, Lachmann HJ (2017) Safety and efficacy of empirical interleukin-1 Inhibition using Anakinra in AA amyloidosis of uncertain aetiology. Amyloid 24(3):189\u2013193. https:\/\/doi.org\/10.1080\/13506129.2017.1352503","journal-title":"Amyloid"},{"issue":"1","key":"6030_CR83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000343398","volume":"37","author":"M Yilmaz","year":"2013","unstructured":"Yilmaz M, Unsal A, Sokmen M et al (2013) Renal involvement in AA amyloidosis: clinical outcomes and survival. Kidney Blood Press Res 37(1):33\u201342. https:\/\/doi.org\/10.1159\/000343398","journal-title":"Kidney Blood Press Res"},{"issue":"7","key":"6030_CR84","first-page":"644","volume":"19","author":"E Ahbap","year":"2014","unstructured":"Ahbap E, Kara E, Sahutoglu T et al (2014) Outcome of 121 patients with renal amyloid a amyloidosis. J Res Med Sci Off J Isfahan Univ Med Sci 19(7):644","journal-title":"J Res Med Sci Off J Isfahan Univ Med Sci"},{"issue":"6","key":"6030_CR85","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.rbre.2017.02.002","volume":"57","author":"Y Ayar","year":"2017","unstructured":"Ayar Y, Ersoy A, Oksuz MF et al (2017) Clinical outcomes and survival in AA amyloidosis patients. Revista Brasileira de Reumatologia (English Edition) 57(6):535\u2013544. https:\/\/doi.org\/10.1016\/j.rbre.2017.02.002","journal-title":"Revista Brasileira de Reumatologia (English Edition)"},{"issue":"1","key":"6030_CR86","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000343407","volume":"36","author":"Y Koc","year":"2012","unstructured":"Koc Y, Basturk T, Unsal A et al (2012) Effects of AA amyloidosis on survival in peritoneal dialysis. Kidney Blood Press Res 36(1):182\u2013190. https:\/\/doi.org\/10.1159\/000343407","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"6030_CR87","doi-asserted-by":"publisher","first-page":"c119","DOI":"10.1159\/000081553","volume":"98","author":"MR Alt\u0131parmak","year":"2004","unstructured":"Alt\u0131parmak MR, Pamuk \u00d6N, Ataman R, Serdenge\u00e7ti K (2004) Continuous ambulatory peritoneal dialysis in Familial Mediterranean fever amyloidosis patients with End-Stage renal failure: a Single-Centre experience from Turkey. Nephron Clin Pract 98(4):c119\u2013c123. https:\/\/doi.org\/10.1159\/000081553","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"6030_CR88","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/08860220601166560","volume":"29","author":"S Sahin","year":"2007","unstructured":"Sahin S, Manga Sahin G, Ergin H, Kantarci G (2007) The effect of dialytic modalities on clinical outcomes in ESKD patients with Familial Mediterranean fever. Ren Fail 29(3):315\u2013319. https:\/\/doi.org\/10.1080\/08860220601166560","journal-title":"Ren Fail"},{"issue":"4","key":"6030_CR89","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000168121","volume":"10","author":"A Martinez-Vea","year":"1990","unstructured":"Martinez-Vea A, Garc&iacute;a C, Carreras M, Revert L, Angel Oliver J (1990) End-stage renal disease in systemic amyloidosis: clinical course and outcome on dialysis. Am J Nephrol 10(4):283\u2013289. https:\/\/doi.org\/10.1159\/000168121","journal-title":"Am J Nephrol"},{"issue":"3","key":"6030_CR90","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.ajkd.2023.07.020","volume":"83","author":"C Schwarz","year":"2024","unstructured":"Schwarz C, Georgin-Lavialle S, Lombardi Y et al (2024) Kidney transplantation in patients with AA amyloidosis: outcomes in a French multicenter cohort. Am J Kidney Dis 83(3):329\u2013339. https:\/\/doi.org\/10.1053\/j.ajkd.2023.07.020","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"6030_CR91","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15(7):387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4","journal-title":"Nat Rev Neurol"},{"issue":"21","key":"6030_CR92","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1016\/S0021-9258(19)42128-5","volume":"249","author":"Y Kanda","year":"1974","unstructured":"Kanda Y, Goodman DS, Canfield RE, Morgan FJ (1974) The amino acid sequence of human plasma prealbumin. J Biol Chem 249(21):6796\u20136805","journal-title":"J Biol Chem"},{"issue":"10","key":"6030_CR93","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/PL00000791","volume":"58","author":"JA Hamilton","year":"2001","unstructured":"Hamilton JA, Benson MD (2001) Transthyretin: a review from a structural perspective. Cell Mol Life Sci 58(10):1491\u20131521. https:\/\/doi.org\/10.1007\/PL00000791","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"6030_CR94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin amyloid outcome Survey). J Am Coll Cardiol 68(2):161\u2013172. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6030_CR95","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer,Mathew S, Suhr OB (2013) THAOS \u2013 The transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29(1):63\u201376. https:\/\/doi.org\/10.1185\/03007995.2012.754348","journal-title":"Curr Med Res Opin"},{"key":"6030_CR96","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Paolantonio AD, Bisogni G, Sabatelli M (2020) Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care<\/p>. Ther Clin Risk Manag 16:109\u2013123. https:\/\/doi.org\/10.2147\/TCRM.S219979","journal-title":"Ther Clin Risk Manag"},{"issue":"15_supplement","key":"6030_CR97","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.1251","volume":"96","author":"D Brown","year":"2021","unstructured":"Brown D, Vera-Llonch M, Ortiz JT et al (2021) Use of commercial claims data to estimate hereditary transthyretin-mediated amyloidosis prevalence and incidence in the US (1251). Neurology 96(15_supplement):1251. https:\/\/doi.org\/10.1212\/WNL.96.15_supplement.1251","journal-title":"Neurology"},{"issue":"1","key":"6030_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03547-0","volume":"20","author":"D Delgado","year":"2025","unstructured":"Delgado D, Dabbous F, Shivappa N et al (2025) Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis 20(1):29. https:\/\/doi.org\/10.1186\/s13023-025-03547-0","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"6030_CR99","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2215\/CJN.08720811","volume":"7","author":"L Lobato","year":"2012","unstructured":"Lobato L, Rocha A (2012) Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 7(8):1337. https:\/\/doi.org\/10.2215\/CJN.08720811","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"6030_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11080980","volume":"11","author":"PM Ferraro","year":"2021","unstructured":"Ferraro PM, D\u2019Ambrosio V, Di Paolantonio A et al (2021) Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience. Brain Sci 11(8):980. https:\/\/doi.org\/10.3390\/brainsci11080980","journal-title":"Brain Sci"},{"key":"6030_CR101","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2022e12284","volume":"55","author":"VA Feitosa","year":"2022","unstructured":"Feitosa VA, Neves PDMM, Jorge LB, Noronha IL, Onuchic LF (2022) Renal amyloidosis: a new time for a complete diagnosis. Braz J Med Biol Res 55:e12284. https:\/\/doi.org\/10.1590\/1414-431X2022e12284","journal-title":"Braz J Med Biol Res"},{"key":"6030_CR102","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1159\/000526955","volume":"53","author":"M Allinovi","year":"2022","unstructured":"Allinovi M, Bergesio F, Cappelli F et al (2022) Is hereditary transthyretin amyloidosis the third leading cause of monogenic chronic kidney disease, only behind ADPKD and Alport disease? Am J Nephrol 53:624\u2013627. https:\/\/doi.org\/10.1159\/000526955","journal-title":"Am J Nephrol"},{"key":"6030_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1242815","volume":"14","author":"L Poli","year":"2023","unstructured":"Poli L, Labella B, Cotti Piccinelli S et al (2023) Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol 14:1242815. https:\/\/doi.org\/10.3389\/fneur.2023.1242815","journal-title":"Front Neurol"},{"issue":"9","key":"6030_CR104","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","volume":"15","author":"J Solignac","year":"2022","unstructured":"Solignac J, Delmont E, Fortanier E et al (2022) Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. Clin Kidney J 15(9):1747. https:\/\/doi.org\/10.1093\/ckj\/sfac118","journal-title":"Clin Kidney J"},{"issue":"2\u20133","key":"6030_CR105","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","volume":"498","author":"MJM Saraiva","year":"2001","unstructured":"Saraiva MJM (2001) Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 498(2\u20133):201\u2013203. https:\/\/doi.org\/10.1016\/S0014-5793(01)02480-2","journal-title":"FEBS Lett"},{"issue":"29","key":"6030_CR106","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1074\/jbc.M101024200","volume":"276","author":"A Quintas","year":"2001","unstructured":"Quintas A, Vaz DC, Cardoso I, Saraiva MJM, Brito RMM (2001) Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants*. J Biol Chem 276(29):27207\u201327213. https:\/\/doi.org\/10.1074\/jbc.M101024200","journal-title":"J Biol Chem"},{"issue":"36","key":"6030_CR107","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.1021\/bi00151a036","volume":"31","author":"W Colon","year":"1992","unstructured":"Colon W, Kelly JW (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31(36):8654\u20138660. https:\/\/doi.org\/10.1021\/bi00151a036","journal-title":"Biochemistry"},{"issue":"20","key":"6030_CR108","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1021\/bi952501g","volume":"35","author":"Z Lai","year":"1996","unstructured":"Lai Z, Col\u00f3n W, Kelly JW (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35(20):6470\u20136482. https:\/\/doi.org\/10.1021\/bi952501g","journal-title":"Biochemistry"},{"issue":"6","key":"6030_CR109","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","volume":"27","author":"P Morfino","year":"2022","unstructured":"Morfino P, Aimo A, Panichella G, Rapezzi C, Emdin M (2022) Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail Rev 27(6):2187\u20132200. https:\/\/doi.org\/10.1007\/s10741-022-10237-7","journal-title":"Heart Fail Rev"},{"issue":"23","key":"6030_CR110","doi-asserted-by":"publisher","first-page":"13158","DOI":"10.3390\/ijms222313158","volume":"22","author":"A Gonzalez-Duarte","year":"2021","unstructured":"Gonzalez-Duarte A, Ulloa-Aguirre A (2021) A brief journey through protein misfolding in transthyretin amyloidosis (ATTR amyloidosis). Int J Mol Sci 22(23):13158. https:\/\/doi.org\/10.3390\/ijms222313158","journal-title":"Int J Mol Sci"},{"key":"6030_CR111","doi-asserted-by":"publisher","unstructured":"He S, He X, Liu L et al (2021) The structural Understanding of transthyretin misfolding and the inspired drug approaches for the treatment of heart failure associated with transthyretin amyloidosis. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.628184","DOI":"10.3389\/fphar.2021.628184"},{"issue":"46","key":"6030_CR112","doi-asserted-by":"publisher","first-page":"32943","DOI":"10.1074\/jbc.274.46.32943","volume":"274","author":"A Quintas","year":"1999","unstructured":"Quintas A, Saraiva MJM, Brito RMM (1999) The tetrameric protein transthyretin dissociates to a non-native monomer in solution: a NOVEL MODEL FOR AMYLOIDOGENESIS*. J Biol Chem 274(46):32943\u201332949. https:\/\/doi.org\/10.1074\/jbc.274.46.32943","journal-title":"J Biol Chem"},{"key":"6030_CR113","doi-asserted-by":"publisher","unstructured":"Yamaguchi H, Kawahara H, Kodera N et al (2022) Extracellular vesicles contribute to the metabolism of transthyretin amyloid in hereditary transthyretin amyloidosis. Front Mol Biosci 9. https:\/\/doi.org\/10.3389\/fmolb.2022.839917","DOI":"10.3389\/fmolb.2022.839917"},{"issue":"4","key":"6030_CR114","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr OB, Lundgren E, Westermark P (2017) One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med 281(4):337\u2013347. https:\/\/doi.org\/10.1111\/joim.12585","journal-title":"J Intern Med"},{"issue":"37","key":"6030_CR115","doi-asserted-by":"publisher","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","volume":"293","author":"PP Mangione","year":"2018","unstructured":"Mangione PP, Verona G, Corazza A et al (2018) Plasminogen activation triggers transthyretin amyloidogenesis in vitro. J Biol Chem 293(37):14192\u201314199. https:\/\/doi.org\/10.1074\/jbc.RA118.003990","journal-title":"J Biol Chem"},{"issue":"4","key":"6030_CR116","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1073\/pnas.1317488111","volume":"111","author":"PP Mangione","year":"2014","unstructured":"Mangione PP, Porcari R, Gillmore JD et al (2014) Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A 111(4):1539. https:\/\/doi.org\/10.1073\/pnas.1317488111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6030_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7010011","volume":"7","author":"H Koike","year":"2019","unstructured":"Koike H, Katsuno M (2019) Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines 7(1):11. https:\/\/doi.org\/10.3390\/biomedicines7010011","journal-title":"Biomedicines"},{"key":"6030_CR118","doi-asserted-by":"publisher","unstructured":"Phan TH, Reed JH (2024) Extracellular vesicles as next-generation therapeutics and biomarkers in amyloidosis: a new frontier. Front Biomater Sci 2. https:\/\/doi.org\/10.3389\/fbiom.2023.1343658","DOI":"10.3389\/fbiom.2023.1343658"},{"issue":"49","key":"6030_CR119","doi-asserted-by":"publisher","first-page":"38176","DOI":"10.1074\/jbc.M002886200","volume":"275","author":"MM Sousa","year":"2000","unstructured":"Sousa MM, Norden AGW, Jacobsen C et al (2000) Evidence for the role of megalin in renal uptake of transthyretin *. J Biol Chem 275(49):38176\u201338181. https:\/\/doi.org\/10.1074\/jbc.M002886200","journal-title":"J Biol Chem"},{"issue":"2","key":"6030_CR120","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","volume":"9","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M (2020) Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 9(2):317\u2013333. https:\/\/doi.org\/10.1007\/s40120-020-00210-7","journal-title":"Neurol Ther"},{"key":"6030_CR121","doi-asserted-by":"publisher","unstructured":"Gasperini RJ, Klaver DW, Hou X, Aguilar MI, Small DH (2012) Mechanisms of Transthyretin Aggregation and Toxicity. In: Harris JR (ed) Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. Springer Netherlands, pp 211\u2013224. https:\/\/doi.org\/10.1007\/978-94-007-5416-4_9","DOI":"10.1007\/978-94-007-5416-4_9"},{"issue":"1","key":"6030_CR122","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","volume":"63","author":"H Koike","year":"2004","unstructured":"Koike H, Misu K, Sugiura M et al (2004) Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63(1):129\u2013138. https:\/\/doi.org\/10.1212\/01.WNL.0000132966.36437.12","journal-title":"Neurology"},{"key":"6030_CR123","doi-asserted-by":"publisher","unstructured":"(2024) https:\/\/onlinelibrary-wiley-com.ezp-prod1.hul.harvard.edu\/doi\/abs\/https:\/\/doi.org\/10.1111\/j.1699-0463.1975.tb01878.x","DOI":"10.1111\/j.1699-0463.1975.tb01878.x"},{"issue":"5","key":"6030_CR124","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000522370","volume":"146","author":"R Fenoglio","year":"2022","unstructured":"Fenoglio R, Baldovino S, Barreca A et al (2022) Renal involvement in transthyretin amyloidosis: the double presentation of transthyretin amyloidosis deposition disease. Nephron 146(5):481\u2013488. https:\/\/doi.org\/10.1159\/000522370","journal-title":"Nephron"},{"issue":"3","key":"6030_CR125","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/joneph\/16.3.438","volume":"16","author":"L Lobato","year":"2003","unstructured":"Lobato L (2003) Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). J Nephrol 16(3):438\u2013442","journal-title":"J Nephrol"},{"issue":"7","key":"6030_CR126","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/ndt\/gfh063","volume":"19","author":"R Snanoudj","year":"2004","unstructured":"Snanoudj R, Durrbach A, Gauthier E et al (2004) Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrol Dial Transplant 19(7):1779\u20131785. https:\/\/doi.org\/10.1093\/ndt\/gfh063","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"6030_CR127","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/brain\/110.2.315","volume":"110","author":"N IKEDA SI, HANYU","year":"1987","unstructured":"IKEDA SI, HANYU N, HONGO M et al (1987) HEREDITARY GENERALIZED AMYLOIDOSIS WITH POLYNEUROPATHY: CLINICOPATHOLOGICAL STUDY OF 65 JAPANESE PATIENTS. Brain 110(2):315\u2013337. https:\/\/doi.org\/10.1093\/brain\/110.2.315","journal-title":"Brain"},{"issue":"3","key":"6030_CR128","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","volume":"18","author":"L Lobato","year":"2003","unstructured":"Lobato L, Beir\u00e3o I, Silva M et al (2003) Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transpl 18(3):532\u2013538. https:\/\/doi.org\/10.1093\/ndt\/18.3.532","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"6030_CR129","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/13506120410001673884","volume":"11","author":"L Lobato","year":"2004","unstructured":"Lobato L, Beir\u00e3o I, Silva M et al (2004) End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid 11(1):27\u201337. https:\/\/doi.org\/10.1080\/13506120410001673884","journal-title":"Amyloid"},{"issue":"1","key":"6030_CR130","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS et al (2022) Long-term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 15(1):e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193","journal-title":"Circ Heart Fail"},{"issue":"2","key":"6030_CR131","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/ahe.13.10","volume":"9","author":"RC Givens","year":"2013","unstructured":"Givens RC, Russo C, Green P, Maurer MS (2013) Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health 9(2):229\u2013235. https:\/\/doi.org\/10.2217\/ahe.13.10","journal-title":"Aging Health"},{"issue":"4","key":"6030_CR132","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","volume":"4","author":"E Gonzalez-Lopez","year":"2022","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L et al (2022) Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol 4(4):442. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.007","journal-title":"JACC CardioOncol"},{"issue":"1","key":"6030_CR133","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10286-019-00623-x","volume":"29","author":"JA Palma","year":"2019","unstructured":"Palma JA, Gonzalez-Duarte A, Kaufmann H (2019) Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Auton Res 29(1):33\u201344. https:\/\/doi.org\/10.1007\/s10286-019-00623-x","journal-title":"Clin Auton Res"},{"issue":"9","key":"6030_CR134","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1681\/ASN.V1091972","volume":"10","author":"D Rubinger","year":"1999","unstructured":"Rubinger D, Sapoznikov D, Pollak A, Popovtzer MM, Luria MH (1999) Heart rate variability during chronic hemodialysis and after renal transplantation: studies in patients without and with systemic amyloidosis. J Am Soc Nephrol 10(9):1972. https:\/\/doi.org\/10.1681\/ASN.V1091972","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"6030_CR135","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000511723","volume":"50","author":"L Yang","year":"2021","unstructured":"Yang L, Zhao Y, Qiao B et al (2021) Heart rate variability and prognosis in hemodialysis patients: a meta-analysis. Blood Purif 50(3):298\u2013308. https:\/\/doi.org\/10.1159\/000511723","journal-title":"Blood Purif"},{"issue":"sup1","key":"6030_CR136","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/13506129.2011.574354071","volume":"18","author":"L Lobato","year":"2011","unstructured":"Lobato L, Beir\u00e3o I, Seca R et al (2011) Combined liver\u2013kidney transplantation in familial amyloidotic polyneuropathy TTR V30M: nephrological assessment. Amyloid 18(sup1):190\u2013192. https:\/\/doi.org\/10.3109\/13506129.2011.574354071","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"6030_CR137","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","volume":"10","author":"P Westermark","year":"2003","unstructured":"Westermark P, Bergstr\u00f6m J, Solomon A, Murphy C, Sletten K (2003) Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 10(Suppl 1):48\u201354","journal-title":"Amyloid"},{"key":"6030_CR138","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijcard.2023.03.063","volume":"382","author":"F Cappelli","year":"2023","unstructured":"Cappelli F, Del Franco A, Vergaro G et al (2023) Prevalence of transthyretin-related amyloidosis in Tuscany: data from the regional population-based registry. Int J Cardiol 382:87\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2023.03.063","journal-title":"Int J Cardiol"},{"issue":"11","key":"6030_CR139","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao L, Buxbaum JN, Reixach N (2013) Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52(11):1913\u20131926. https:\/\/doi.org\/10.1021\/bi301313b","journal-title":"Biochemistry"},{"issue":"3","key":"6030_CR140","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/labinvest.3780246","volume":"81","author":"Mhui Teng","year":"2001","unstructured":"Teng Mhui, Yin Jyun, Vidal R et al (2001) Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 81(3):385\u2013396. https:\/\/doi.org\/10.1038\/labinvest.3780246","journal-title":"Lab Invest"},{"issue":"4","key":"6030_CR141","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/cts.12469","volume":"10","author":"V Slowik","year":"2017","unstructured":"Slowik V, Apte U (2017) Leukocyte cell-derived chemotaxin-2: it\u2019s role in pathophysiology and future in clinical medicine. Clin Transl Sci 10(4):249\u2013259. https:\/\/doi.org\/10.1111\/cts.12469","journal-title":"Clin Transl Sci"},{"issue":"1","key":"6030_CR142","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0165-2478(96)02572-2","volume":"52","author":"S Yamagoe","year":"1996","unstructured":"Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, Suzuki K (1996) Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 52(1):9\u201313. https:\/\/doi.org\/10.1016\/0165-2478(96)02572-2","journal-title":"Immunol Lett"},{"issue":"2","key":"6030_CR143","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/ki.2008.152","volume":"74","author":"MD Benson","year":"2008","unstructured":"Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B (2008) Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int 74(2):218\u2013222. https:\/\/doi.org\/10.1038\/ki.2008.152","journal-title":"Kidney Int"},{"issue":"2","key":"6030_CR144","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/ki.2014.11","volume":"86","author":"CP Larsen","year":"2014","unstructured":"Larsen CP, Kossmann RJ, Beggs ML, Solomon A, Walker PD (2014) Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int 86(2):378\u2013382. https:\/\/doi.org\/10.1038\/ki.2014.11","journal-title":"Kidney Int"},{"issue":"11","key":"6030_CR145","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2215\/CJN.12551214","volume":"10","author":"SH Nasr","year":"2015","unstructured":"Nasr SH, Dogan A, Larsen CP (2015) Leukocyte cell\u2013derived chemotaxin 2\u2013associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol 10(11):2084. https:\/\/doi.org\/10.2215\/CJN.12551214","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"6030_CR146","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/13506129.2016.1145110","volume":"23","author":"CP Larsen","year":"2016","unstructured":"Larsen CP, Beggs ML, Wilson JD, Lathrop SL (2016) Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in new Mexico. Amyloid 23(2):119\u2013123. https:\/\/doi.org\/10.3109\/13506129.2016.1145110","journal-title":"Amyloid"},{"issue":"4","key":"6030_CR147","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/modpathol.2016.29","volume":"29","author":"CP Larsen","year":"2016","unstructured":"Larsen CP, Ismail W, Kurtin PJ, Vrana JA, Dasari S, Nasr SH (2016) Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Mod Pathol 29(4):416\u2013420. https:\/\/doi.org\/10.1038\/modpathol.2016.29","journal-title":"Mod Pathol"},{"issue":"6","key":"6030_CR148","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1053\/j.ajkd.2010.08.013","volume":"56","author":"CL Murphy","year":"2010","unstructured":"Murphy CL, Wang S, Kestler D et al (2010) Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 56(6):1100\u20131107. https:\/\/doi.org\/10.1053\/j.ajkd.2010.08.013","journal-title":"Am J Kidney Dis"},{"key":"6030_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107231","author":"JH Ha","year":"2024","unstructured":"Ha JH, Xu Y, Sekhon H et al (2024) Mimicking kidney flow shear efficiently induces aggregation of LECT2, a protein involved in renal amyloidosis. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2024.107231","journal-title":"J Biol Chem"},{"issue":"9","key":"6030_CR150","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ki.2010.9","volume":"77","author":"CP Larsen","year":"2010","unstructured":"Larsen CP, Walker PD, Weiss DT, Solomon A (2010) Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int 77(9):816\u2013819. https:\/\/doi.org\/10.1038\/ki.2010.9","journal-title":"Kidney Int"},{"issue":"29","key":"6030_CR151","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029638","volume":"101","author":"H Xu","year":"2022","unstructured":"Xu H, Jia Y, Wang X, Wang H, Yu J, Hao W (2022) Renal amyloidogenic leukocyte chemotactic factor 2 combined with IgA nephropathy: a case report. Medicine Baltimore 101(29):e29638. https:\/\/doi.org\/10.1097\/MD.0000000000029638","journal-title":"Medicine Baltimore"},{"issue":"2","key":"6030_CR152","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000479678","volume":"7","author":"G Kaur","year":"2017","unstructured":"Kaur G, Bijin B, Saleem K, Sarsah B, Thajudeen B (2017) Leukocyte cell-derived chemotaxin 2-associated renal amyloidosis: a case report. Case Rep Nephrol Dial 7(2):121. https:\/\/doi.org\/10.1159\/000479678","journal-title":"Case Rep Nephrol Dial"},{"issue":"2","key":"6030_CR153","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/ki.2013.558","volume":"86","author":"SM Said","year":"2014","unstructured":"Said SM, Sethi S, Valeri AM et al (2014) Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int 86(2):370\u2013377. https:\/\/doi.org\/10.1038\/ki.2013.558","journal-title":"Kidney Int"},{"issue":"2","key":"6030_CR154","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/ndt\/gfw375","volume":"33","author":"T Rezk","year":"2018","unstructured":"Rezk T, Gilbertson JA, Rowczenio D et al (2018) Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrol Dial Transplant 33(2):241\u2013247. https:\/\/doi.org\/10.1093\/ndt\/gfw375","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"6030_CR155","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1053\/j.ajkd.2018.10.016","volume":"74","author":"JM Mejia-Vilet","year":"2019","unstructured":"Mejia-Vilet JM, C\u00e1rdenas-Mastrascusa LR, Palacios-Cebreros EJ et al (2019) LECT2 amyloidosis in kidney transplantation: a report of 5 cases. Am J Kidney Dis 74(4):563\u2013566. https:\/\/doi.org\/10.1053\/j.ajkd.2018.10.016","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"6030_CR156","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.xkme.2020.11.019","volume":"3","author":"SH Nasr","year":"2021","unstructured":"Nasr SH, Chavez O, Dasari S et al (2021) Donor-derived ALECT2 amyloidosis and recurrent fibrillary glomerulonephritis in a transplant allograft. Kidney Med 3(3):433\u2013437. https:\/\/doi.org\/10.1016\/j.xkme.2020.11.019","journal-title":"Kidney Med"},{"key":"6030_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.869409","volume":"9","author":"ZY Li","year":"2022","unstructured":"Li ZY, Wang S, Li DY, Liu D, Wang SX, Yu XJ, Liu G, Zhou FD, Zhao MH (2022) Fibrinogen A alpha-chain amyloidosis in two Chinese patients. Front Med (Lausanne) 9:869409. https:\/\/doi.org\/10.3389\/fmed.2022.869409","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"6030_CR158","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ekir.2016.11.005","volume":"2","author":"D Rowczenio","year":"2016","unstructured":"Rowczenio D, Stensland M, de Souza GA, Str\u00f8m EH, Gilbertson JA, Taylor G, Rendell N, Minogue S, Efebera YA, Lachmann HJ, Wechalekar AD, Hawkins PN, Heimdal KR, Selvig K, L\u00e6greid IK, Demoulin N, Aydin S, Gillmore JD, Wien TN (2016) Renal amyloidosis associated with 5 novel variants in the fibrinogen A alpha chain protein. Kidney Int Rep 2(3):461\u2013469. https:\/\/doi.org\/10.1016\/j.ekir.2016.11.005","journal-title":"Kidney Int Rep"},{"issue":"2","key":"6030_CR159","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/13506129.2015.1037389","volume":"22","author":"M Yazaki","year":"2015","unstructured":"Yazaki M, Yoshinaga T, Sekijima Y, Nishio S, Kanizawa Y, Kametani F, Miyashita K, Hachiya N, Higuchi K, Ikeda S (2015) The first pure form of Ostertag-type amyloidosis in Japan: a sporadic case of hereditary fibrinogen A\u03b1-chain amyloidosis associated with a novel frameshift variant. Amyloid 22(2):142\u20134. https:\/\/doi.org\/10.3109\/13506129.2015.1037389","journal-title":"Amyloid"},{"issue":"1","key":"6030_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010320","volume":"19","author":"M Yazaki","year":"2018","unstructured":"Yazaki M, Yoshinaga T, Sekijima Y, Kametani F, Okumura N (2018) Hereditary Fibrinogen A\u03b1-Chain Amyloidosis in Asia: Clinical and Molecular Characteristics. Int J Mol Sci 19(1):320. https:\/\/doi.org\/10.3390\/ijms19010320","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6030_CR161","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1681\/ASN.2008060614","volume":"20","author":"JD Gillmore","year":"2009","unstructured":"Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 20(2):444\u201351. https:\/\/doi.org\/10.1681\/ASN.2008060614","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"6030_CR162","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/j.1523-1755.2005.00653.x","volume":"68","author":"HG Kang","year":"2005","unstructured":"Kang HG, Bybee A, Ha IS, Park MS, Gilbertson JA, Cheong HI, Choi Y, Hawkins PN (2005) Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aalpha chain gene. Kidney Int 68(5):1994\u20138. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00653.x","journal-title":"Kidney Int"},{"issue":"15","key":"6030_CR163","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood-2009-06-223792","volume":"115","author":"AJ Stangou","year":"2010","unstructured":"Stangou AJ, Banner NR, Hendry BM, Rela M, Portmann B, Wendon J, Monaghan M, Maccarthy P, Buxton-Thomas M, Mathias CJ, Liepnieks JJ, O\u2019Grady J, Heaton ND, Benson MD (2010) Hereditary fibrinogen A \u03b1-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115(15):2998\u20133007. https:\/\/doi.org\/10.1182\/blood-2009-06-223792","journal-title":"Blood"},{"issue":"2","key":"6030_CR164","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/rth2.12191","volume":"3","author":"M Pieters","year":"2019","unstructured":"Pieters M, Wolberg AS (2019) Fibrinogen and fibrin: an illustrated review. Res Pract Thromb Haemost 3(2):161\u2013172. https:\/\/doi.org\/10.1002\/rth2.12191","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"6030_CR165","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ekir.2021.07.014","volume":"6","author":"S Jin","year":"2021","unstructured":"Jin S, Shen Z, Li J, Lin P, Xu X, Ding X, Liu H (2021) Fibrinogen A Alpha-Chain Amyloidosis Associated With a Novel Variant in a Chinese Family. Kidney Int Rep 6(10):2726\u20132730. https:\/\/doi.org\/10.1016\/j.ekir.2021.07.014","journal-title":"Kidney Int Rep"},{"issue":"2","key":"6030_CR166","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11255-024-04236-w","volume":"57","author":"L He","year":"2025","unstructured":"He L, Zhou J, Wang M, Chen J, Liu C, Shi J, Rui Y, Wu H (2025) Clinical manifestations, diagnosis and treatment of hereditary fibrinogen A\u03b1-chain renal amyloidosis: one case report and systematic review. Int Urol Nephrol 57(2):517\u2013533. https:\/\/doi.org\/10.1007\/s11255-024-04236-w","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"6030_CR167","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/14789450.2019.1659137","volume":"16","author":"J Chapman","year":"2019","unstructured":"Chapman J, Dogan A (2019) Fibrinogen alpha amyloidosis: insights from proteomics. Expert Rev Proteomics 16(9):783\u2013793. https:\/\/doi.org\/10.1080\/14789450.2019.1659137","journal-title":"Expert Rev Proteomics"},{"issue":"10","key":"6030_CR168","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1182\/blood.2024026386","volume":"146","author":"N Ranjit Anderson","year":"2025","unstructured":"Ranjit Anderson N, Dorbala S, Mollee P (2025) Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis. Blood 146(10):1157\u20131162. https:\/\/doi.org\/10.1182\/blood.2024026386","journal-title":"Blood"},{"key":"6030_CR169","doi-asserted-by":"publisher","unstructured":"Baker KR (2022) Light chain amyloidosis: epidemiology, staging, and prognostication. Methodist Debakey Cardiovasc J 18(2):27\u201335.\u00a0https:\/\/doi.org\/10.14797\/mdcvj.1070","DOI":"10.14797\/mdcvj.1070"},{"key":"6030_CR170","doi-asserted-by":"publisher","unstructured":"Dima D, Mazzoni S, Anwer F, Khouri J, Samaras C, Valent J, Williams L (2023) Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation. JCO Oncol Pract (5):265\u2013275.\u00a0https:\/\/doi.org\/10.1200\/OP.22.00396","DOI":"10.1200\/OP.22.00396"},{"key":"6030_CR171","doi-asserted-by":"publisher","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Sch\u00f6nland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL (2021) ANDROMEDA Trial investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385(1):46\u201358.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2028631","DOI":"10.1056\/NEJMoa2028631"},{"key":"6030_CR172","doi-asserted-by":"publisher","unstructured":"Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K (2022) Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 18(10):591\u2013602. https:\/\/doi.org\/10.1038\/s41584-022-00827-y","DOI":"10.1038\/s41584-022-00827-y"},{"key":"6030_CR173","doi-asserted-by":"publisher","unstructured":"Karam C, Mauermann ML, Gonzalez-Duarte A, Kaku MC, Ajroud-Driss S, Brannagan TH 3rd, Polydefkis M (2024) Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts. Muscle Nerve 69(3):273\u2013287.\u00a0https:\/\/doi.org\/10.1002\/mus.28026","DOI":"10.1002\/mus.28026"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-06030-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-06030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-06030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:31:19Z","timestamp":1779240679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-06030-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":173,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6030"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-06030-y","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A.H and R.B.C declare they have no financial and non-financial interests that are directly or indirectly related to the work submitted for publication. G.B has received honoraria for consulting engagements from Prothena and Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}